Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry

被引:22
作者
Maes, A. [1 ]
Garre, B. [1 ,2 ]
Desmet, N. [1 ]
van der Meulen, K. [2 ]
Nauwynck, H. [2 ]
De Backer, P. [1 ]
Croubels, S. [1 ]
机构
[1] Univ Ghent, Fac Med Vet, Dept Pharmacol Toxicol Biochem & Organ Physiol, B-9820 Merelbeke, Belgium
[2] Univ Ghent, Fac Med Vet, Virol Lab, B-9820 Merelbeke, Belgium
关键词
acyclovir; ganciclovir; HPLC-fluorescence; LC-MS/MS; quantification; validation; plasma; body fluids (nasal fluid; PBMC; cerebrospinal fluid); SOLID-PHASE EXTRACTION; HUMAN SERUM; GANCICLOVIR; PHARMACOKINETICS; VALIDATION; TISSUES; URINE; ASSAY; HPLC; SKIN;
D O I
10.1002/bmc.1093
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Two methods are presented for the determination of 'respectively' the plasma protein unbound and total concentration of acyclovir in horse plasma and body fluids: first, a liquid-liquid extraction was performed on plasma, combined with HPLC-fluorescence detection for the total plasma concentration; second a more sensitive method using high-performance liquid chromatography combined with heated electrospray ionization tandem mass spectrometry (LC-HESI-MS/MS) was described for plasma and for body fluids analysis. To obtain the unbound concentration of acyclovir in plasma, a simple deproteinization step using a Microcon (R) filter was performed. Ganciclovir was used as an internal standard. Analysis was carried out on an Inertsil 5 ODS-3 column for the HPLC-fluorescence method. For the LC-HESI-MS/MS method a PLRP-S column was used. The limit of quantification (LOQ) for the total concentration was set at 50 and 2 ng mL(-1) for the HPLC-fluorescence method and the LC-HESI-MS/MS method, respectively. The limit of quantification for the unbound concentration was set at 5 ng mL(-1) and at 2 ng mL(-1) for body fluids. The methods were successfully used to perform pharmacokinetic and clinical studies in horses after intravenous and oral dosage of acyclovir and its prodrug valacyclovir. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 1856, RULES GOVERNING MED, P3
[2]   Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies [J].
Bahrami, G ;
Mirzaei, S ;
Kiani, A .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 816 (1-2) :327-331
[3]   Rapid, simple and sensitive high-performance liquid chromatographic method for detection and determination of acyclovir in human plasma and its use in bioavailability studies [J].
Bangaru, RA ;
Bansal, YK ;
Rao, ARM ;
Gandhi, TP .
JOURNAL OF CHROMATOGRAPHY B, 2000, 739 (02) :231-237
[4]  
Basavaiah K., 2003, Farmaco (Lausanne), V58, P1301, DOI 10.1016/S0014-827X(03)00157-5
[5]  
BLUM MR, 1982, AM J MED, V73, P186
[6]   Determination of acyclovir in human plasma by high-performance liquid chromatography [J].
Boulieu, R ;
Gallant, C ;
Silberstein, N .
JOURNAL OF CHROMATOGRAPHY B, 1997, 693 (01) :233-236
[7]   Hydrophilic interaction liquid chromatography/electrospray mass spectrometry determination of acyclovir in pregnant rat plasma and tissues [J].
Brown, SD ;
White, CA ;
Bartlett, MG .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (19) :1871-1876
[8]   Determination of acyclovir in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography [J].
Brown, SD ;
White, CA ;
Chu, CK ;
Bartlett, MG .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 772 (02) :327-334
[9]  
De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI [10.1016/j.jcv.2004.02.009, 10.1002/rmv.439]
[10]   HPLC determination of acyclovir in skin layers and percutaneous penetration samples [J].
de Jalón, EG ;
Campanero, MA ;
Ygartua, P ;
Santoyo, S .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2002, 25 (20) :3187-3197